两句话理解的对吗？谢谢

Belimumab: Decreases activation of B cells. When used in addition to standard therapy, patients on belimumab showed improvement in cutaneous and musculoskeletal disease. Belimumab-treated patients had decreased SLE activity, a reduced time to disease flare, and lower glucocorticoid exposure. Safety data were good. Patients with central nervous system or serious kidney disease were excluded. 

4. Abatacept: Downregulates T cell activation. Data is limited regarding improvement in arthritis, fatigue, sleep if added to routine therapy. Negative data as adjunct agent for lupus arthritis when added to MMF or CYC.

1. 贝利木单抗：减少B细胞的激活。在标准治疗的基础上，加用贝利木单抗的患者在皮肤和肌肉骨骼疾病方面表现出改善。接受贝利木单抗治疗的患者SLE活动减少，疾病爆发时间缩短，糖皮质激素使用降低。安全数据良好。但做研究时排除了有中枢神经系统或严重肾脏疾病的患者。

2. Abatacept：下调T细胞活化。如果加入常规治疗，对于关节炎、疲劳、睡眠改善的数据有限。因阴性数据当其添加到MMF或CYC作为狼疮性关节炎治疗用药时时只能作为辅助药物。